Drugs & Targets FDA clears the way for multi-center investigator-initiated study of Alpha DaRT in immunocompromised patients with recurrent cSCC October 11, 2024Vol.50 No.38
Drugs & Targets FDA grants clearance for radiation oncology tool to calculate absorbed dose of radionuclides October 11, 2024Vol.50 No.38
Drugs & Targets First in-office digital hub enhances provider efficiency and communication October 11, 2024Vol.50 No.38
Drugs & Targets Genetics and sequencing company join to explore the UG 100TM sequencing platform to advance clinical test offerings in oncology and reproductive genomics October 11, 2024Vol.50 No.38
Regulatory News ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitorsVote may lead to rollback of some indications held by BMS and Merck October 04, 2024Vol.50 No.37By Jacquelyn Cobb
Guest Editorial NCI-designated Basic Laboratory Cancer Centers get research done—efficiently October 04, 2024Vol.50 No.37By Ze’ev Ronai
Cancer History ProjectConversation with The Cancer Letter Tom Lynch reflects on discovery of the EGFR mutations’ role in lung cancer October 04, 2024Vol.50 No.37By Paul Goldberg and McKenzie Prillaman
In Brief Kevin Holcomb joins Northwell as chair of obstetrics and gynecology October 04, 2024Vol.50 No.37
